MedKoo Cat#: 407879 | Name: CM03

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CM03 is a potent inhibitor of cell growth in PDAC cell lines, and has anticancer activity in PDAC models, with a superior profile compared to gemcitabine, a commonly used therapy. Whole-transcriptome RNA-seq methodology has been used to analyze the effects of this quadruplexbinding small molecule on global gene expression. This has revealed the down-regulation of a large number of genes, rich in putative quadruplex elements and involved in essential pathways of PDAC survival, metastasis, and drug resistance. The changes produced by CM03 represent a global response to the complexity of human PDAC and may be applicable to other currently hard-to-treat cancers.

Chemical Structure

CM03
CM03
CAS#2101208-44-8 (free base)

Theoretical Analysis

MedKoo Cat#: 407879

Name: CM03

CAS#: 2101208-44-8 (free base)

Chemical Formula: C34H44N6O6

Exact Mass: 632.3322

Molecular Weight: 632.76

Elemental Analysis: C, 64.54; H, 7.01; N, 13.28; O, 15.17

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
2101208-44-8 (free base) 2101208-52-8 (HCl) 2101208-53-9 (2HCl) 2101208-54-0 (3HCl)
Synonym
CM03; CM-03; CM 03.
IUPAC/Chemical Name
2,7-bis(3-morpholinopropyl)-4-((2-(pyrrolidin-1-yl)ethyl)amino)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone
InChi Key
KCCGFZWBVFNFGW-UHFFFAOYSA-N
InChi Code
InChI=1S/C34H44N6O6/c41-31-24-5-6-25-29-28(24)26(33(43)39(31)12-3-10-37-15-19-45-20-16-37)23-27(35-7-14-36-8-1-2-9-36)30(29)34(44)40(32(25)42)13-4-11-38-17-21-46-22-18-38/h5-6,23,35H,1-4,7-22H2
SMILES Code
O=C(N(CCCN1CCOCC1)C(C2=C3C4=C(C(N5CCCN6CCOCC6)=O)C=C2NCCN7CCCC7)=O)C3=CC=C4C5=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Human pancreatic ductal adenocarcinoma (PDAC) involves the dysregulation of multiple signaling pathways.

Preparing Stock Solutions

The following data is based on the product molecular weight 632.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma with a G-Quadruplex-Binding Small Molecule Chiara Marchetti, Katherine G. Zyner, Stephan A. Ohnmacht, Mathew Robson, Shozeb M. Haider, Jennifer P. Morton, Giovanni Marsico, Tam Vo, Sarah Laughlin-Toth, Ahmed A. Ahmed, Gloria Di Vita, Ingrida Pazitna, Mekala Gunaratnam, Rachael J. Besser, Ana C. G. Andrade, Seckou Diocou, Jeremy A. Pike, David Tannahill, R. Barbara Pedley, T. R. Jeffry Evans, W. David Wilson, Shankar Balasubramanian, and Stephen Neidle Publication Date (Web): January 22, 2018 (Article) DOI: 10.1021/acs.jmedchem.7b01781